Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Thursday, October 23 2014 3:57am ET - U.S. Markets open in 5 hours and 33 minutes.
Industry Center
Industry Center > > Genentech, Inc. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
Genentech, Inc. Company Profile
"The few, the proud, the profitable" could be Genentech's motto. One of the world's oldest and most successful biotechs (in an industry full of money-losers), the firm has a number of blockbuster cancer therapies based on its antibody (protein) technologies. Its oncology portfolio contains Rituxan (non-Hodgkin's lymphoma), Avastin (colorectal and lung cancers), Herceptin (breast cancer), Tarceva (lung cancer), Xeloda (metastatic colorectal cancer), and Zelboraf (inoperable melanoma). Other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Genentech is wholly owned by Swiss pharma powerhouse Roche.
Headlines for Genentech, Inc.
NewLink Genetics rises on Roche cancer partnership
- Mon Oct 20
Regeneron's Eylea works better vs Avastin and Lucentis in study
- Fri Oct 17
NewLink in $1 billion deal with Roche to develop cancer drug
- Mon Oct 20
Doctors Net Billions From Drug Firms
- Tue Sep 30
NewLink-Roche Ink Deal for Oncology Candidate Development
- Tue 5:05 pm ET
Ahead of the Bell: Exelixis shares soar
- Mon Sep 29
FDA says asthma drug Xolair raises risk of heart, brain problems
- Fri Sep 26
Canada urged to cancel Ebola vaccine licence, transfer rights to bigger company
- Mon Oct 20
25 years after Bay Area quake, most don't have earthquake insurance
- Fri Oct 17
PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations
- Thu Oct 16
Contact Information
Address: 1 DNA Way
South San Francisco, CA 94080-4990
Phone:650-225-1000
Fax:650-225-6000
Financial Highlights
Fiscal Year End:December
Key People
EVP Research and Early Development Center: Richard H. Scheller
VP Government Affairs: Walter K. Moore
SVP Procurement and Contract Manufacturing Operations: Markus Gemuend
Industry Information
Sector:
Industry:
Top Competitors
GlaxoSmithKline plc (gsk)
Novartis AG (nvs)
Sanofi (sny)
 


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?